<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7336">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935220</url>
  </required_header>
  <id_info>
    <org_study_id>1218.55</org_study_id>
    <nct_id>NCT00935220</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients</brief_title>
  <official_title>An Open Label, Phase I Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Linagliptin (BI 1356) 5 mg After Single and Multiple Oral Administration in Patients With Type 2 Diabetes Mellitus of African American Origin for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to investigate the pharmacokinetics and pharmacodynamics of
      linagliptin (BI 1356) 5 mg administered orally in patients with Type 2 diabetes mellitus of
      African American origin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Linagliptin: AUC_τ,ss</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>area under the concentration time curve (AUC_τ) of linagliptin in plasma at steady state over a uniform dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin: C_max,ss</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>maximum concentration of linagliptin in plasma at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DPP-4 Inhibition: E_24,ss</measure>
    <time_frame>One single measurement 24 h after drug administration under steady state conditions</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma DPP-4 inhibition at trough under steady state conditions. Plasma DPP-4 inhibition is derived by calculating (1-(activity in presence of linagliptin)/baseline activity))*100%, where 'activity' is the activity of the DPP-IV enzyme.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency of patients with AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities Reported as an Adverse Event</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with Electrocardiogram (ECG), vital signs, physical finding reported as an adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: AUC_0-24</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>area under the concentration time curve of linagliptin in plasma over the time interval from 0 to 24h after administration of the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: C_max</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>maximum concentration of linagliptin in plasma on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DPP-4 Inhibition: E_24</measure>
    <time_frame>One single measurement 24 h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma DPP-4 inhibition 24 hours after first dose. Plasma DPP-4 inhibition is derived by calculating (1-(activity in presence of linagliptin)/baseline activity))*100%, where 'activity' is the activity of the DPP-IV enzyme.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin QD (once daily) for 7 days</intervention_name>
    <description>dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration</description>
    <arm_group_label>linagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Glycosylated haemoglobin &gt;=7 and &lt;= 10%

          2. Age &gt;=21 and &lt;= 65

          3. Body Mass Index &gt;=18.5 and &lt;=38 kg/m2

          4. African American origin

          5. Signed and dated informed consent prior to admission to the study

        Exclusion criteria:

          1. Any finding of the medical examination considered clinically relevant by the
             Investigator

          2. Clinically relevant concomitant diseases like renal insufficiency, cardiac
             insufficiency New York Heart Association (NYHA) II-IV, known cardiovascular disease
             including hypertension &gt;160-100 mmHg (under current treatment), stroke and transient
             ischemic attack (TIA).

          3. Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological or hormonal disorders besides type 2 diabetes

          4. Clinically relevant diseases of central nervous system or psychiatric disorders or
             relevant neurological disorders besides polyneuropathy

          5. Diagnosis of sickle cell anemia or known chronic anemia

          6. History of chronic or relevant infections (for example human immunodeficieny virus
             (HIV), Hepatitis B)

          7. History of relevant allergy/hypersensitivity

          8. Intake of drugs with a long half life (&gt;24hours) within at least one month or less
             than 10 half lives of the respective drug prior to administration except allowed co
             medication

          9. Alcohol abuse, drug abuse

         10. Any laboratory value of clinical relevance that is outside an acceptable range

         11. Change of drug dosing of allowed co medication

         12. Any (electrocardiogram) ECG value outside the reference range and of clinical
             relevance.

         13. Fasted glucose &gt;270 mg/dl or randomly determined blood glucose &gt;400 mg/dl on two
             consecutive days during screening or wash out

         14. Serum creatinine above upper limit normal at screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.55.0006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.55.0008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.55.0004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.55.0005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.55.0003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.55.0001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.55_U11-3076-01_DS.pdf</url>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.55_Literature.pdf</url>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>June 17, 2014</lastchanged_date>
  <firstreceived_date>July 1, 2009</firstreceived_date>
  <firstreceived_results_date>August 22, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin 5mg</title>
          <description>Linagliptin 5mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin 5mg</title>
          <description>Linagliptin 5mg once daily</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50.5" spread="9.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Black / African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body mass index (BMI) continuous</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30.93" spread="3.90"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Emergent Adverse Events</title>
        <description>Frequency of patients with AEs</description>
        <time_frame>21 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Treatment Emergent Adverse Events</title>
            <description>Frequency of patients with AEs</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Patients with any adverse events (AEs)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients with severe AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients with drug-related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discontinuation due to AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</title>
        <description>12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities</description>
        <time_frame>21 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</title>
            <description>12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ECG abnormalities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vital signs abnormalities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical finding abnormalities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Laboratory finding abnormalities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin: AUC_τ,ss</title>
        <description>area under the concentration time curve (AUC_τ) of linagliptin in plasma at steady state over a uniform dosing interval</description>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Linagliptin: AUC_τ,ss</title>
            <description>area under the concentration time curve (AUC_τ) of linagliptin in plasma at steady state over a uniform dosing interval</description>
            <units>nmol*h/L</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="194" spread="25.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin: C_max,ss</title>
        <description>maximum concentration of linagliptin in plasma at steady state</description>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Linagliptin: C_max,ss</title>
            <description>maximum concentration of linagliptin in plasma at steady state</description>
            <units>nmol/L</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16.4" spread="40.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities Reported as an Adverse Event</title>
        <description>Patients with Electrocardiogram (ECG), vital signs, physical finding reported as an adverse event</description>
        <time_frame>21 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patients With Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities Reported as an Adverse Event</title>
            <description>Patients with Electrocardiogram (ECG), vital signs, physical finding reported as an adverse event</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: AUC_0-24</title>
        <description>area under the concentration time curve of linagliptin in plasma over the time interval from 0 to 24h after administration of the first dose</description>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set- All patients with values for the area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24 h after administration of the first dose (AUC_0-24) for Linagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Linagliptin: AUC_0-24</title>
            <description>area under the concentration time curve of linagliptin in plasma over the time interval from 0 to 24h after administration of the first dose</description>
            <units>nmol*h/L</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137" spread="32.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DPP-4 Inhibition: E_24,ss</title>
        <description>Plasma DPP-4 inhibition at trough under steady state conditions. Plasma DPP-4 inhibition is derived by calculating (1-(activity in presence of linagliptin)/baseline activity))*100%, where 'activity' is the activity of the DPP-IV enzyme.</description>
        <time_frame>One single measurement 24 h after drug administration under steady state conditions</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>DPP-4 Inhibition: E_24,ss</title>
            <description>Plasma DPP-4 inhibition at trough under steady state conditions. Plasma DPP-4 inhibition is derived by calculating (1-(activity in presence of linagliptin)/baseline activity))*100%, where 'activity' is the activity of the DPP-IV enzyme.</description>
            <units>Percent (of inhibition)</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="84.7" lower_limit="72.2" upper_limit="91.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: C_max</title>
        <description>maximum concentration of linagliptin in plasma on Day 1</description>
        <time_frame>24h</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set - All patients with values for the maximum measured concentration of linagliptin in plasma (C_max)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Linagliptin: C_max</title>
            <description>maximum concentration of linagliptin in plasma on Day 1</description>
            <units>nmol/L</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.9" spread="57.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DPP-4 Inhibition: E_24</title>
        <description>Plasma DPP-4 inhibition 24 hours after first dose. Plasma DPP-4 inhibition is derived by calculating (1-(activity in presence of linagliptin)/baseline activity))*100%, where 'activity' is the activity of the DPP-IV enzyme.</description>
        <time_frame>One single measurement 24 h after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>DPP-4 Inhibition: E_24</title>
            <description>Plasma DPP-4 inhibition 24 hours after first dose. Plasma DPP-4 inhibition is derived by calculating (1-(activity in presence of linagliptin)/baseline activity))*100%, where 'activity' is the activity of the DPP-IV enzyme.</description>
            <units>Percent (of inhibition)</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75.2" lower_limit="52.0" upper_limit="89.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin 5mg</title>
          <description>Linagliptin 5mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra (13,0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
